荣昌生物 (688331)

RemeGen Co., Ltd.

KSH

Tags

SSE 580 IndexLoss-Making StocksImmunotherapyInnovative DrugsPharmaceutical ManufacturingPharmaceuticals and HealthcareContains H-SharesFund Heavy PositionsBiological ProductsSTAR Market 100 IndexSTAR Market Biotechnology IndexMargin Trading and Securities LendingHigh Price-to-Book Ratio医药生物

K-Line Chart

No K-line data available

Company NameRongchang Biopharmaceutical (Yantai) Co., Ltd.
Listing Date2022-03-31
Issue Price48RMB
Registered Capital56360.824310k RMB
Legal RepresentativeWang Weidong
Registered AddressNo. 58 Beijing Middle Road, Yantai Development Zone, Yantai Area, China (Shandong) Pilot Free Trade Zone
IndustryBiological Products
Main BusinessDedicated to the discovery, development, and commercialization of innovative and distinctive first-in-class and best-in-class biologics.
Company ProfileRongchang Biopharmaceutical (Yantai) Co., Ltd. is an innovative biopharmaceutical enterprise with a global vision. Since its establishment, the company has focused on therapeutic antibody drugs, including Antibody-Drug Conjugates (ADCs), antibody fusion proteins, monoclonal antibodies, and bispecific antibodies. The company is committed to discovering, developing, and commercializing innovative and distinctive first-in-class and best-in-class biologics. Guided by the goal of creating clinical value for drugs, it provides safe, effective, and accessible clinical solutions for major disease areas such as autoimmune diseases, oncology, and ophthalmic diseases, aiming to address significant unmet clinical needs. The company possesses the world's first, first-in-class innovative fusion protein product Telitacicept (RC18), which targets both B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL). It also has Disitamab Vedotin (RC48), the first independently developed ADC innovative drug in China and currently the only Chinese ADC product granted Breakthrough Therapy Designation by the U.S. FDA.

Stock Details

1. Key Indicators

  • Total Shares(W): 56360.82
  • Circulating A-Shares(W): 16222.39
  • Earnings Per Share(RMB): -1.0100
  • Net Assets Per Share(RMB): 4.1165
  • Operating Revenue(W RMB): 171983.30
  • Total Profit(W RMB): -55070.06
  • **Net Profit Attributable to Parent(W RMB) **: -55070.06
  • Net Profit Growth Rate(%): 48.60
  • Weighted Return on Equity(%): -26.7000
  • Operating Cash Flow Per Share(RMB): 0.3850
  • Undistributed Profit Per Share(RMB): -8.6453
  • Capital Reserve Per Share(RMB): 12.2847

2. Main Business

The main business covers:

  • Antibody-drug conjugates (ADC)
  • Antibody fusion proteins
  • Monoclonal antibodies and bispecific antibodies

3. Company Basic Information

  • Company Name: Rongchang Biotech
  • Listing Date: No Information
  • Industry: No Information
  • Address: No Information
  • Website: No Information
  • Company Profile: No Information

4. Top 10 Circulating Shareholders

Rank Institution Name Institution Type Shares Held (W) Percentage Held (%)
No Data Available

5. Concept Sectors

  • No concept sector information available

Remarks

  • Data update date: 2025-11-04
  • Data source: Public market information